DOCKET NO.: ALZA-0023 (ARC 2865 N1)
Application No.: 09/802,709
Office Action Dated: September 9, 2003

PATENT
REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-36. **(Previously Canceled)**

~~37.~~ 1 **(Previously amended)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 5.5 hours following said administration.

38-45. **(Previously Canceled)**

2 ~~46.~~ **(Previously Presented)** The method of claim ~~37~~ 1 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 4 to about 5.5 hours.

C1

3 ~~47.~~ **(Previously Presented)** The method of claim ~~37~~ 1 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 8 hours.

4 ~~48.~~ **(Previously Presented)** The method of claim ~~37~~ 1 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 9.5 hours.

5 ~~49.~~ **(Previously Presented)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that

achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 8 hours following said administration.

6

~~50.~~ **(Previously Presented)** A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 9.5 hours following said administration.